EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 654 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR FDA Approves First Comprehensive Pan-Tumour Liquid Biopsy Test for Patients with... September 3, 2020 FDA Approves Belzutifan for Advanced Renal Cell Carcinoma January 19, 2024 Health-Conscious Coffee Drinkers Are Ditching the Cream and Sugar in Favor... February 3, 2020 Telisotuzumab Vedotin Associated with Durable Responses in c-Met Protein–Overexpressing Non-Squamous EGFR-wild-type... August 5, 2024 Load more HOT NEWS Patient Guide in Prostate Cancer Now Available Also in German Common Questions About COVID-19 and Cancer: Answers for Patients and Survivors Genetic discovery could guide treatment for aggressive childhood cancer Screening for Many Cancers with One Test: Uncertainty Abounds
